ADVM vs. SGMO, CHRS, BDTX, CRTX, CCCC, VALN, ITOS, LXEO, KYTX, and ADPT
Should you be buying Adverum Biotechnologies stock or one of its competitors? The main competitors of Adverum Biotechnologies include Sangamo Therapeutics (SGMO), Coherus BioSciences (CHRS), Black Diamond Therapeutics (BDTX), Cortexyme (CRTX), C4 Therapeutics (CCCC), Valneva (VALN), iTeos Therapeutics (ITOS), Lexeo Therapeutics (LXEO), Kyverna Therapeutics (KYTX), and Adaptive Biotechnologies (ADPT). These companies are all part of the "medical" sector.
Sangamo Therapeutics (NASDAQ:SGMO) and Adverum Biotechnologies (NASDAQ:ADVM) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, community ranking, institutional ownership, dividends, earnings, analyst recommendations, media sentiment and profitability.
Sangamo Therapeutics has a beta of 1.35, suggesting that its stock price is 35% more volatile than the S&P 500. Comparatively, Adverum Biotechnologies has a beta of 1.13, suggesting that its stock price is 13% more volatile than the S&P 500.
Adverum Biotechnologies has lower revenue, but higher earnings than Sangamo Therapeutics. Adverum Biotechnologies is trading at a lower price-to-earnings ratio than Sangamo Therapeutics, indicating that it is currently the more affordable of the two stocks.
Adverum Biotechnologies has a net margin of 0.00% compared to Adverum Biotechnologies' net margin of -1,749.06%. Sangamo Therapeutics' return on equity of -90.38% beat Adverum Biotechnologies' return on equity.
Sangamo Therapeutics received 75 more outperform votes than Adverum Biotechnologies when rated by MarketBeat users. Likewise, 62.71% of users gave Sangamo Therapeutics an outperform vote while only 60.87% of users gave Adverum Biotechnologies an outperform vote.
In the previous week, Adverum Biotechnologies' average media sentiment score of 0.00 equaled Sangamo Therapeutics'average media sentiment score.
56.9% of Sangamo Therapeutics shares are owned by institutional investors. Comparatively, 48.2% of Adverum Biotechnologies shares are owned by institutional investors. 2.8% of Sangamo Therapeutics shares are owned by insiders. Comparatively, 4.2% of Adverum Biotechnologies shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Sangamo Therapeutics presently has a consensus target price of $5.67, suggesting a potential upside of 886.71%. Adverum Biotechnologies has a consensus target price of $29.00, suggesting a potential upside of 294.56%. Given Adverum Biotechnologies' higher probable upside, research analysts clearly believe Sangamo Therapeutics is more favorable than Adverum Biotechnologies.
Summary
Sangamo Therapeutics and Adverum Biotechnologies tied by winning 8 of the 16 factors compared between the two stocks.
Get Adverum Biotechnologies News Delivered to You Automatically
Sign up to receive the latest news and ratings for ADVM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ADVM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Adverum Biotechnologies Competitors List
Related Companies and Tools
